This article was originally published in The Gray Sheet
Genetic MicroSystems will operate as a wholly owned facility of Affymetrix following the completion of an acquisition agreement valued at roughly $101 mil. and announced Sept. 13 (1"The Gray Sheet" Sept. 20, p. 20)
You may also be interested in...
Acquisition of privately held DNA array technology firm Genetic MicroSystems for 1 mil. shares of common stock valued at about $101 mil. is outlined in a definitive agreement announced Sept. 13. The Woburn, Massachusetts based firm's product line, which includes the GMS 417 arrayer and GMS 418 array scanner, will complement Affymetrix' high-volume GeneChip platform. The deal is expected to close in Jan. 2000. Separately, the U.S. Patent and Trademark Office Board of Patent Appeals and Interferences rules in favor of Affymetrix in patent interference proceedings with Palo Alto, California-based Incyte Pharmaceuticals. The board's decision, which Incyte intends to appeal, says that Incyte did not provide sufficient evidence that Affymetrix' claims were not supported by written description or enablement
Device Week, 4 December 2020 – MedWatch Question About Third-Party Servicers Slides Under Industry's Radar
On this week’s podcast: A change made by the US FDA to its MedWatch program that asks adverse event reporters whether a third party serviced a malfunctioning medical device went unnoticed by many in industry for nearly a year. We explain why, and tell how the servicer question will be helpful for manufacturers and the agency.
The series D financing will support the expansion of Everlywell’s consumer lab testing and digital health businesses.